A5053319727- Pericarditis and Cardiac Tamponade
- Lipoproteins and Cardiovascular Health
- Myasthenia Gravis and Thymoma
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Atrial Fibrillation Management and Outcomes
- Infective Endocarditis Diagnosis and Management
- Cardiac tumors and thrombi
- Adrenal Hormones and Disorders
- Dermatology and Skin Diseases
- Urticaria and Related Conditions
- Monoclonal and Polyclonal Antibodies Research
- Vasculitis and related conditions
- COVID-19 Clinical Research Studies
- Takotsubo Cardiomyopathy and Associated Phenomena
- Hormonal Regulation and Hypertension
- Cardiac Imaging and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Diabetes Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Atherosclerosis and Cardiovascular Diseases
- Peptidase Inhibition and Analysis
- Cell Adhesion Molecules Research
- Cardiac Arrhythmias and Treatments
- Cholesterol and Lipid Metabolism
- Pharmacology and Obesity Treatment
Synta Pharmaceuticals (United States)
2019-2024
Kaneka (United States)
2021-2023
Cleveland Clinic
2020
Cerenis Therapeutics (France)
2013-2017
Clinical Research Institute
2014
Duke University Hospital
1994-2014
Duke Medical Center
1992-2014
The University of Western Australia
2014
Harvard University
2014
University of Münster
2014
The use of warfarin reduces the rate ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent predictable anticoagulation than warfarin.
Patients with non-valvular atrial fibrillation (AF) and renal insufficiency are at increased risk for ischaemic stroke bleeding during anticoagulation. Rivaroxaban, an oral, direct factor Xa inhibitor metabolized predominantly by the liver, preserves benefit of warfarin prevention while causing fewer intracranial fatal haemorrhages.We randomized 14 264 patients AF in a double-blind trial to rivaroxaban 20 mg/day [15 if creatinine clearance (CrCl) 30-49 mL/min] or dose-adjusted (target...
Background— Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to the Rivaroxaban Once Daily, Oral, Direct Factor Inhibition Compared With Vitamin K Antagonism for Prevention Stroke and Embolism Trial Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes older younger patients. Methods Results— There were 6229...
High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL failed to show benefits vs. placebo. To investigate the effects an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). A prospective, double-blinded, randomized trial was conducted at 51 centres in USA, Netherlands, Canada, France. Intravascular QCA were performed assess baseline 3 (2–5)...
Interleukin-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety rilonacept, an interleukin-1α interleukin-1β cytokine trap, were studied previously in phase 2 trial involving patients with pericarditis.We conducted 3 multicenter, double-blind, event-driven, randomized-withdrawal rilonacept acute symptoms pericarditis (as assessed on patient-reported scale) systemic inflammation shown by elevated C-reactive protein [CRP] level). Patients presenting...
Background and Purpose— Intracranial hemorrhage (ICH) is a life-threatening complication of anticoagulation. Methods— We investigated the rate, outcomes, predictors ICH in 14 264 patients with atrial fibrillation from Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention Stroke Embolism Trial Atrial Fibrillation (ROCKET AF). Cox proportional hazards modeling was used. Results— During 1.94 years (median) follow-up, 172 (1.2%) experienced...
Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy GM-CSF receptor antagonist mavrilimumab maintaining disease remission. Methods This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed arteritis 50 centres (North America, Europe, Australia). Active within 6 weeks baseline was required for inclusion. Patients glucocorticoid-induced...
Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha Beta for Recurrent Pericarditis: A Pivotal Symptomatology Outcomes Study). The long‐term extension further explored recurrent natural history treatment duration decision‐making during 24 additional months open‐label rilonacept treatment. Methods Results Seventy‐four patients commenced extension, with...
GPR109A is not the target mediating niacin’s lipid efficacy and free fatty acid hypothesis does explain mechanism of action.
CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and phospholipids that was designed to mimic the beneficial properties nascent pre-β HDL. In this study, we have evaluated capacity perform reverse lipid transport in single dose studies as well regress atherosclerosis LDLr(-/-) mice after short-term multiple-dose infusions.CER-001 induced cholesterol efflux from macrophages exhibited anti-inflammatory response similar natural Studies with HUVEC demonstrated at...
Abstract Prurigo nodularis (PN) is a chronic skin dermatosis with hyperkeratotic and intensely pruritic nodules. Managing PN‐associated itch difficult because its aetiology still unknown. This study aimed to investigate the correlation between intensity in PN expression of pruritogenic cytokine interleukin (IL)‐31, receptor complex components IL‐31 α (IL‐31RA) oncostatin M β (OSMRβ), (OSM), which ligand OSMR β, through immunofluorescence staining examination. Itch was closely correlated...
Human samples of patients with chronic pericarditis and appropriate control subjects were stained for the inflammasome components. A mouse model was developed through intrapericardial injection zymosan A. Different blockers tested in model. Patients presented an intensification activation compared subjects. The experimental showed pathological features pericarditis. Among blockers, NLRP3 inhibitor, anakinra, interleukin-1 trap found to significantly improve pericardial alterations....
In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated respiratory failure and death. We aimed to evaluate whether mavrilimumab, monoclonal antibody GM-CSF receptor, would improve outcomes in COVID-19 pneumonia systemic hyperinflammation.This investigator-initiated, multicentre, double-blind, randomised trial was done at seven hospitals USA. Inclusion required hospitalisation, pneumonia,...
Effective and safe therapies are needed for the treatment of patients with giant cell arteritis (GCA). Emerging as a key cytokine in inflammation, granulocyte-macrophage colony stimulating factor (GM-CSF) may play role promoting inflammation GCA.
Improving lipids beyond low-density lipoprotein cholesterol (LDL-C) lowering with statin monotherapy may further reduce cardiovascular risk. Niacin has complementary lipid-modifying efficacy to statins and benefit, but is underutilised because of flushing, mediated primarily by prostaglandin D(2) (PGD(2)). Laropiprant (LRPT), a PGD(2) receptor (DP1) antagonist that reduces niacin-induced flushing been combined extended-release niacin (ERN) into fixed-dose tablet.Dyslipidaemic patients were...